ArticleBMC microbiology2025
Contribution of icaADBC genes in biofilm production ability of Staphylococcus aureus clinical isolates collected from hospitalized patients at a burn center in North of Iran.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Synthesis and biological evaluation of tris(4-methoxyphenyl)phosphonium-hydrazone derivatives against clinical methicillin-resistant Staphylococcus aureus (MRSA) isolates: antibacterial, antibiofilm, and gene expression analyses.Folia microbiologica · 2026Article
- Controlling Staphylococcus aureus skin infections by targeting biofilm and virulence properties using FDA-approved antiseptics and skin care products.Folia microbiologica · 2026Article
- Biofilm Production, Distribution ofAntibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionThe pathogenicity of Staphylococcus aureus is significantly attributed to its capacity to produce biofilms, which bolster bacterial resistance against antibiotics and host immune responses. This study aimed to explore the involvement of icaABCD genes in biofilm formation ability of S. aureus clinical isolates. MATERIALS AND
methodsOne hundred clinical S. aureus isolates were collected from hospitalized patients at a burn center in North of Iran. The isolates were identified using standard biochemical tests and confirmed by the presence of the nuc gene. Antibiotic susceptibility profiles were determined through the disk agar diffusion method. Biofilm formation capacity was determined using microtiter plate assay. PCR test was conducted to detect the presence of icaABCD genes.
resultsPenicillin exhibited the highest resistance rate (94%), while vancomycin was most effective antibiotic with 6% resistance. Besides, 32% of the isolates demonstrated as multidrug resistant (MDR) and 29% were Methicillin-resistant S. aureus (MRSA). Notably, 89% of the isolates were identified as biofilm produces, while 54 (60.67%), 28 (31.46%), and 7 (7.86%) isolates exhibited strong, moderate, and weakly biofilm production ability, respectively. PCR results revealed a prevalence of 90%, 92%, 92%, and 94% for the icaA, icaB, icaC, and icaD genes, respectively. Intriguingly, the MDR isolates exhibited a 100% prevalence of these genes. Similarly, 96.55%, 89.65%, 89.65% and 96.55% of the MRSA isolates were carrying the icaA, icaB, icaC, and icaD genes, respectively.
conclusionThis study revealed a noteworthy prevalence of biofilm-producing strains of S. aureus. High prevalence of icaADBC genes as well as highlighted capacity of the biofilm formation in MRSA and MDR strains exhibited a potential correlation between biofilm and antibiotic resistance patterns. Given the enhanced resilience of bacteria within biofilms against antibiotics, addressing biofilm production is imperative alongside antibiotic treatments for effective control and eradication of infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.